

Publications:

1. Agarwal A, Guindo A, Cissoko Y, **Taylor JG**, Coulibaly D, Kayentao K, Djimde A, Plowe CV, Doumbo O, Wellem TE, Diallo D. 2000. Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. *Blood* 96(7): 2358-2363.
2. **Taylor JG**, Tang D, Foster CB, Serjeant GR, Rodgers GP, Chanock SJ. 2002. Patterns of low affinity immunoglobulin receptor polymorphisms in stroke and sickle cell disease. *Am J Hematol* 69(2): 109-114.
3. **Taylor JG**, Tang DC, Savage S, Leitman SF, Heller SI, Serjeant GR, Rodgers GP, Chanock SJ. 2002. Variants in the *VCAM1* gene and risk for symptomatic stroke in sickle cell disease. *Blood* 100(13): 4303-4309.
Commentary in Blood: SS disease is not a single gene disorder. Dover, GJ. *Blood* 100(13):4255.
4. Choi E, Foster CB, **Taylor JG**, Erichsen HC, Chen RA, Walsh TJ, Anttila VJ, Ruutu T, Palotie A, Chanock SJ. 2003. Chronic disseminated candidiasis in adult leukemia patients is associated with a common *IL4* promoter haplotype in a pilot study. *J Infect Dis* 187(7): 1153-1156.
5. Bernig T, **Taylor JG**, Foster CB, Staats B, Yeager M, Chanock SJ. 2004. Sequence analysis of the mannose binding lectin *MBL2* gene reveals a high degree of heterozygosity and evidence of selection. *Genes Immun* 5(6): 461-76.
6. Eck P*, Erichsen HC*, **Taylor JG**, Yeager M, Hughes AL, Levine M, Chanock SJ. 2004. Comparison of the genomic structure and variation in the two human sodium dependent vitamin C transporters, *SLC23A1* and *SLC23A2*. *Hum Genet* 115: 285-294.
7. Choi EH, **Taylor JG**, Foster CB, Walsh TJ, Anttila VJ, Ruutu T, Palotie A, Chanock SJ. 2005. Common polymorphisms in critical genes of innate immunity do not contribute to the risk for chronic disseminated candidiasis in adult leukemia patients. *Med Mycol* 43(4):349-53.
8. Kato GJ, McGowan V, Machado RF, Little JA, **Taylor J**, Morris CR, JS Nichols, Wang X, Poljakovic M, Morris, Jr. SM, Gladwin MT. 2006. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. *Blood* 107(6):2279-85.
9. Kato GJ, Hsieh M, Machado R, **Taylor J**, Little J, Butman JA, Lehky T, Tisdale J, Gladwin MT. 2006. Cerebrovascular disease associated with sickle cell pulmonary hypertension. *Am J Hematol* 81(7):503-10.
10. Little JA, McGowan V, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, **Taylor JG**, Machado RF, Heller T, Castro O, Gladwin MT. 2006. Combination Erythropoietin-Hydroxyurea Therapy in Sickle Cell Disease: NIH experience and literature review. *Haematologica* 91(8):1076-83.
11. Idelman G*, **Taylor JG***, Tongbai R, Chen RA, Haggerty CA, Bilke S, Chanock SJ, Gardner K. 2007. Uncommon polymorphisms of the *VCAM1* promoter prevalent in African American populations are hyperinducible. *Hum Mutat* 28(8):824-9.

12. Sebastiani P, Nolan VG, Baldwin C, Abad-Grau M, Wang L, Adewoye AH, McMahon LC, Farrer LA, **Taylor JG**, Kato GJ, Gladwin MT, Steinberg MH. 2007. A Network Model to Predict the Risk of Death in Sickle Cell Disease. *Blood* 110(7):2727-35.
13. Eck P, Erichsen HC, **Taylor JG**, Corpe C, Chanock SJ, Levine M. 2007. Genomic and functional analysis of the sodium-dependent vitamin C transporter SLC23A1-SVCT1. *Genes Nutr.* 2(1):143-5.
14. **Taylor JG**†, Ackah D, Cobb C, Orr N, Percy MJ, Sachdev V, Machado R, Castro O, Kato G, Chanock SJ, Gladwin MT. 2008. Mutations and Polymorphisms in Hemoglobin Genes and Risk of Pulmonary Hypertension and Death in Sickle Cell Disease. *Am J Hematol* 83(1):6-14.
15. Gordeuk VR, Sachdev V, **Taylor JG**, Gladwin MT, Kato G, Castro OL. 2008. Relative Systemic Hypertension in Patients with Sickle Cell Disease is Associated with Risk of Pulmonary Hypertension and Renal Insufficiency. *Am J Hematol* 83(1):15-18.
16. **Taylor JG**†, Woods GM, Machado R, Kato GJ, Gladwin MT. 2008. Severe Pulmonary Hypertension in an Adolescent with Sickle Cell Disease. *Am J Hematol* 83(1):71-72.
17. Kumkhaek C, **Taylor JG**, Zhu J, Hoppe C, Kato GJ, Rodgers GP. 2008. Fetal Hemoglobin Response to Hydroxyurea Treatment and SAR1A Promoter Polymorphisms in Sickle Cell Anemia. *Br J Haematol* 141(2):254-9.
18. **Taylor JG***†, Nolan VG*, Kato GJ, Gladwin MT, Steinberg MH. 2008. Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain. *PLOS One* 3(5):e2095.
19. Shoham S, Pic-Aluas L, **Taylor J**, Cortez C, Rinaldi M, Shea Y, Walsh TJ. 2008. Transplant Associated Ochroconis gallopava Infections. *Transpl Infect Dis* 10(6):442-8.
20. Darbari DS, Castro O, **Taylor JG**, Fasano R, Rehm J, Gordeuk VR, Minniti CP. 2008. Severe Vaso-Occlusive Episodes Associated with Use of Systemic Corticosteroids in Patients with Sickle Cell Disease: Case Series and Review of Literature. *J Natl Med Assoc* 100(8):948-51.
21. Little JA, Partovi Hauser K, Martyr SE, Harris A, Maric I, Morris CR, Suh HT, **Taylor JG**, Castro OL, Machado RF, Kato GJ, Gladwin MT. 2009. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. *Eur J Haematol* 82(4):315-21.
22. Kato GJ, Wang Z, Machado RF, Blackwelder WC, **Taylor JG**, Hazen SL. 2009. Endogenous Nitric Oxide Synthase Inhibitors in Sickle Cell Disease: Abnormal Levels and Correlations with Pulmonary Hypertension, Desaturation, Hemolysis, Organ Dysfunction and Death. *Br J Haematol* 145(4):506-13.
23. Olnes M, Chi A, Haney C, May R, Minniti C, **Taylor J**, Kato GJ. 2009. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. *Am J Hematol* 84(8):530-32.
24. **Taylor JG***, Cheuk AT*, Tsang PS, Song YK, Desai K, Yu Y, Chen QR, Shah K,

Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Kanna C, Catchpoole D, Qualman SJ, Merlino G, Chanock SJ, Khan J. 2009. Identification of *FGFR4*-activating mutations in human rhabdomyosarcomas which promote metastasis in xenotransplanted models. *J Clin Invest* 119(11):3395–3407.

NIH Press Release: Gene Mutation Linked to Type of Childhood Cancer, October 5, 2009. www.nih.gov/news-events/news-releases/gene-mutation-linked-type-childhood-cancer

Highlighted in Science Daily: Mutated FGFR4 Protein Helps A Childhood Cancer Spread, 5 October 2009. <www.sciencedaily.com/releases/2009/10/091005181225.htm>.

25. Zorca S, Freeman L, Hildesheim M, Allen D, Remaley AT, **Taylor JG**, Kato GJ. 2010. Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. *Br J Haematol* 149(3):436-445.

26. Minniti CP, **Taylor JG**, Hildesheim M, O'Neal P, Wilson J, Castro O, Gordeuk V, Kato GJ. 2011. Laboratory and Echocardiography Markers in Sickle Cell Patients with Leg Ulcers. *Am J Hematol*. 86(8):705-8.

27. Solovieff N, Hartley SW, Baldwin CT, Klings ES, Gladwin MT, **Taylor JG**, Kato GJ, Farrer LA, Steinberg MH, Sebastiani P. 2011. Ancestry of African Americans with sickle cell disease. *Blood Cells Mol. Diseases* 47(1):41-5.

28. Liu P, Barb J, Woodhouse K, **Taylor JG**, Munson PJ, Raghavachari N. 2011. Transcriptome profiling and sequencing of differentiated human hematopoietic stem cells reveal lineage-specific expression and alternative splicing of genes. *Physiol Genomics* 43(20):1117-34.

29. Sachdev V, Kato GJ, Barst RJ, Gibbs SR, Machado RF, Nourai N, Hassell KL, Little JA, Schraufnagel DE, Krishnamurt L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, **Taylor JG**, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR. 2011. Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction are Associated with Exercise Intolerance in Adults and Adolescents with Homozygous Sickle Cell Anemia in the US and UK. *Circulation* 124(13):1452-60.

30. **Taylor JG†**, Darbari DS, Maric I, McIver Z, Arthur DC. 2011. Therapy-Related Acute Myelogenous Leukemia in a Hydroxyurea-Treated Patient With Sickle Cell Anemia. *Ann Intern Med* 155(10): 722-724.

31. Darbari DS, Onyekwere O, Nourai M, Minniti CP, Luchtman-Jones L, Rana S, Sable C, Ensing G, Dham N, Campbell A, Arteta M, Gladwin M, Castro O, **Taylor JG**, Kato GJ, Gordeuk. 2012. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. *J Pediatr* 160(2):286-90.

32. Bae HT, Baldwin CT, Sebastiani P, Telen MJ, Ashley-Koch A, Garrett M, Hooper WC, Bean CJ, Debaun MR, Arking DE, Bhatnagar P, Casella JF, Keefer JR, Barron-Casella E, Gordeuk V, Kato GJ, Minniti C, **Taylor J**, Campbell A, Luchtman-Jones L, Hoppe C, Gladwin MT, Zhang Y, Steinberg MH. 2012. Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. *Blood* 120(9):1961-1962.

33. Liu WM, Maivelett J, Kato GJ, **Taylor JG**, Yang WC, Liu YC, Yang YG, Gorbach AM. 2012. Reconstruction of thermographic signals to map perforator vessels in humans. *Quant Infrared Thermogr J* 9(2):123-133.

34. Fricker Z, Levy E, Kleiner D, **Taylor JG**, Koh C, Holland SM, Heller T. 2013. Case Series: Biliary leak after transjugular liver biopsy. *Am J Gastroenterol* 108(1):145-7.
35. Nekhai S, Xu M, Foster A, Kasvosve I, Diaz S, Machado RF, Castro OL, Kato GJ, **Taylor JG***, Gordeuk VR*. 2013. Reduced sensitivity of the ferroportin Q248H mutant to physiologic concentrations of hepcidin. *Haematologica* 98(3):455-63.
36. Mehari A, Alam S, Tian X, Gladwin MT, Cuttica MJ, Barnett CF, Miles G, Xu D, Seamon C, Adams-Graves P, Castro O, Minniti CP, Sachdev V, **Taylor JG**, Kato GJ, Machado RF. 2013. Hemodynamic predictors of mortality in adults with sickle cell disease. *Am J Crit Care Resp Med* 187(8):840-7.
37. Milton JN, Rooks H, Drasar E, McCabe EL, Baldwin CT, Melista E, Gordeuk VR, Nourai M, Kato GR, Minniti C, **Taylor J**, Campbell A, Luchtman-Jones L, Rana S, Castro O, Zhang Y, Thein SL, Sebastiani P, Gladwin MT; Walk-PHAASST Investigators, Steinberg MH. 2013. Genetic determinants of haemolysis in sickle cell anaemia. *Br J Haematol* 161(2):270-8.
38. Darbari DS, Wang Z, Kwak M, Hildesheim M, Nichols J, Allen D, Seamon C, Peters-Lawrence M, Conrey A, Hall MK, Kato GJ, **Taylor JG†**. 2013. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. *PLoS ONE* 8(11): e79923.
39. Belfer I*, Youngblood V*, Darbari DS*, Wang Z, Diaw L, Freeman L, Desai K, Dizon M, Allen D, Cunnington C, Channon K, Milton J, Hartley SW, Nolan V, Kato GJ, Steinberg MH, Goldman D, **Taylor JG†**. 2014. A *GCH1* haplotype confers sex specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia. *Am J Hematol* 89(2):187–193.
40. Darbari DS, Nourai M, **Taylor JG**, Brugnara C, Castro O, Ballas SK. 2014. Alpha thalassaemia and response to hydroxyurea in sickle cell anaemia. *Eur J Haematol*. 92(4):341-5.
41. Milton JN, Gordeuck VR, **Taylor JG**, Gladwin MT, Steinberg MH, Sebastiani P. 2014. Prediction of fetal hemoglobin in sickle cell anemia using an ensemble of genetic risk prediction models. *Circulation: Cardiovascular Genetics* 7(2):110-5.
42. Wang X, Mendelsohn L, Rogers H, Leitman S, Raghavachari N, Yang Y, Yau YY, Tallack M, Perkins A, **Taylor JG**, Noguchi CT, Kato GJ. 2014. Heme-Bound Iron Activates Placenta Growth Factor in Erythroid Cells via Erythroid Krüppel-like Factor. *Blood* 124(6):946-54.
43. Gladwin MT, Barst RJ, Gibbs JSR, Hildesheim M, Sachdev V, Nourai M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig RB, Badesch DB, Lanzkron S, Castro OL, **Taylor JG**, Goldsmith JC, Kato GJ, Gordeuck VR, Machado RF. 2014. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. *PLoS One* 9(7):e99489.
44. Wallen GR*, Minniti CP*, Krumlauf M, Eckes E; Allen D, Oguhebe A, Seamon C, Darbari DS, Hildesheim M, Yang L, Schulden JD, Kato GJ, **Taylor JG†**. 2014. Sleep disturbance, depression and pain in adults with sickle cell disease. *BMC Psychiatry* 14(1):207.
45. Baird JH, Minniti CP, Lee JM, Tian X, Wu C, Jackson M, Alam S, **Taylor JG**, Kato GJ. 2015. Oscillatory haematopoiesis in adults with sickle cell disease treated with

hydroxycarbamide. *Br J Haematol* 168(5):737-46.

46. van Beers EJ, Yang Y, Raghavachari N, Tian X, Allen D, Nichols J, Mendelsohn L, Nekhai S, Gordeuk V, **Taylor JG**, Kato GJ. 2015. Iron, inflammation, and early death in adults with sickle cell disease. *Circ Res* 116(2):298-306.

47. Feld JJ, Kato GJ, Koh C, Shields T, Hildesheim M, Kleiner DE, **Taylor JG**, Sandler N, Douek D, Haynes-Williams V, Nichols JS, Hoofnagle JH, Liang TJ, Gladwin MT, Heller T. 2015. Liver Injury is Associated with Mortality in Sickle Cell Disease. *Aliment Pharmacol Ther* 42(7):912-21.

48. Darbari DS†, Hampson J, Ichesco E, Kadom N, Vezina G, Evangelou I, Clauw DJ, **Taylor JG*†**, Harris RE*†. 2015. High pain burden is associated with altered brain network connectivity in sickle cell disease. *J Pain* 16(11):1077-86.

49. Hosokawa K, Muranski P, Feng X, Keyvanfar K, Townsley DM, Dumitriu B, Chen J, Kajigaya S, **Taylor JG**, Hourigan CS, Barrett AJ, Young NS. 2015. Identification of novel microRNA signatures linked to acquired aplastic anemia. *Haematologica* 100(12):1534-45.

50. Webb RC, Ma Y, Krishnan S, Li Y, Yoon S, Guo X, Feng X, Shi Y, Seidel M, Cho NH, Kurniawan J, Ahad J, Sheth N, **Taylor JG**, Darlington T, Kim J, Chang K, Huang W, Ayers J, Gruebele A, Pielak RM, Slepian MJ, Huang Y, Gorbach AM, Rogers JA. 2015. Epidermal devices for non-invasive, precise and continuous mapping of macrovascular and microvascular blood flow. *Science Advances* 1(9): e1500701.

51. Fitzhugh CD, Hsieh MM, Allen D, Coles WA, Seamon C, Ring M, Zhao X, Minniti C, Rodgers GP, Schechter AN, Tisdale JF, **Taylor JG†**. 2015. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. *PLOS One* 10(11): e0141706.

Highlighted in ASH Clinical News: February 2016, Volume 2(2):45-47.

52. Xia N, Zhang P, Fang F, Wang Z, Rothstein M, Angulo B, Chiang HR, **Taylor JG**, Reijo Pera R. 2016. Transcriptional comparison of human induced dopaminergic neurons and primary midbrain dopaminergic neurons by RNA-seq. *Scientific Reports* 6: 20270.

53. Hosokawa K, Muranski P, Feng X, Townsley DM, Liu B, Knickelbein J, Keyvanfar K, Dumitriu B, Ito S, Kajigaya S, **Taylor JG**, Kaplan MJ, Nussenblatt RJ, Barrett AJ, O'Shea J, Young NS. 2016. High frequency of circulating CD8+ memory stem T cells in acquired aplastic anemia. *J Immunol* 196(4):1568-78.

54. Weir NA, Saiyed R, Alam S, Conrey A, Desai HD, George MP, Keeley JH, Klings ES, Mehari A, **Taylor JG**, Minniti CP, Kato GJ. 2017. Prostacyclin-analog therapy in sickle cell pulmonary hypertension. *Haematologica* 102(5):e163-e165.

55. Darbari DS, Vaughan KJ, Roskom K, Seamon C, Diaw L, Quinn M, Schechter AN, Haythornthwaite JA, Waclawiw MA, Wallen G, Belfer I*, **Taylor JG*†**. Central sensitization associated with fetal hemoglobin levels in adults with sickle cell anemia. *In press Scand J Pain*.

*Denotes equal contributions.

†Corresponding author.

Chapters and Reviews

1. **Taylor JG**, Ferdig MT, Su X-Z, Wellems TE. 2000. Toward quantitative genetic analysis of host and parasite traits in the manifestations of *Plasmodium falciparum* malaria. *Curr Opin Genet Dev* 10: 314-319.
2. **Taylor JG**, Choi E, Foster CB, Chanock SJ. 2001. Using genetic variation to study human disease. *Trends Mol Med* 7(11): 507-512.
3. Chanock SJ, **Taylor JG**. 2002. Using genetic variation to study immunomodulation. *Curr Opin Pharmacol* 2(4):463-469.
4. Aliyu Z, Kato GJ, **Taylor J**, Babadoko A, Mamman AI, Gordeuk VR, Gladwin MT. 2008. Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology and management. *Am J Hematol* 83(1):63-70.
5. Kato GJ, **Taylor JG**. 2010. Pleiotropic Effects of Intravascular Haemolysis on Vascular Homeostasis. *Br J Haematol* 148(5):690-701.
6. Yauk CL, Argueso JL, Auerbach SS, Awadalla P, Davis SR, DeMarini DM, Douglas GR, Dubrova JE, Elespuru RK, Glover TW, Hales BF, Hurles ME, Klein CB, Lupski JR, Manchester DK, Marchetti F, Montpetit A, Mulvihill JJ, Robaire B, Robbins WA, Rouleau G, Shaughnessy DT, Somers CM, **Taylor JG**, Trasler J, Waters MD, Wilson TE, Witt KL, Bishop JB. 2013. Harnessing Genomics to Identify Environmental Determinants of Heritable Disease. *Mutat Res* 752(1):6-9.
7. Youngblood V, **Taylor JG**. 2013. Sequencing PCR Amplified DNA in Lipoprotein and Cardiovascular Disease Research. *Methods Mol Biol* 1027:139-55.
8. Diaw L, Youngblood V, **Taylor JG**. 2013. Introduction to Next Generation Sequencing in Cardiovascular Disease Research. *Methods Mol Biol* 1027:157-79.